АНТИАГРЕГАНТЫ В ТЕРАПИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: ФОКУС НА ПОЖИЛЫХ

Е. А. Ушкалова; С. К. Зырянов; Е. В. Думченко

Статья

АНТИАГРЕГАНТЫ В ТЕРАПИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: ФОКУС НА ПОЖИЛЫХ

Е. А. Ушкалова, С. К. Зырянов, Е. В. Думченко

2017

https://doi.org/10.20996/1819-6446-2017-13-1-124-128

В современных руководствах по лечению фибрилляции предсердий (ФП) в качестве препаратов выбора для профилактики инсульта рекомендуют антикоагулянты, однако в реальной медицинской практике пожилым пациентам часто назначают антиагреганты. Обзор клинических и фармакоэпидемиологических исследований позволяет прийти к заключению, что риск, связанный с применением ацетилсалициловой кислоты (АСК) у пациентов в возрасте ≥75 лет, может превышать потенциальную пользу. Другие антиагреганты плохо изучены у больных ФП. Вопрос о назначении двойной антиагрегантной терапии (АСК+клопидогрел) может быть рассмотрен у пациентов с сопутствующими сердечно-сосудистыми заболеваниями, которые не подходят для антикоагулянтной терапии по каким-либо другим причинам, помимо риска кровотечений, или у пациентов, отказывающихся принимать антикоагулянты. Комбинации антиагрегантов с варфарином или новыми пероральными антикоагулянтами не приводят к снижению риска развития инсульта по сравнению с монотерапией антикоагулянтами, но ассоциируются с более высоким риском кровотечений, поэтому не могут быть рекомендованы.

Ушкалова Е. А., Зырянов С. К., Думченко Е. В. АНТИАГРЕГАНТЫ В ТЕРАПИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: ФОКУС НА ПОЖИЛЫХ. Рациональная Фармакотерапия в Кардиологии. 2017;13(1):124-128. https://doi.org/10.20996/1819-6446-2017-13-1-124-128

Цитирование

Список литературы

1. Pugh D., Pugh J., Mead G.E. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age and ageing. 2011;40(6):675-83.

2. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6Suppl):546S-592S.

3. Lip G.Y., Laroche C., Dan G.A., et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308-19.

4. Hsu J.C., Maddox T.M., Kennedy K., et al. Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. J Am CollCardiol. 2016 ;67(25):2913-23.

5. Ben Freedman S., Gersh B.J., Lip G.Y. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in atrial fibrillation. Eur Heart J. 2015;36:653-6.

6. Bajorek B., Magin P.J., Hilmer S., Krass I. Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice. J Clin Pharm Ther. 2016;41(4):432-40.

7. Linchak R.M., Kompanietz O.G., Nedbaikin A.M., et al. What are the realities of antithrombotic therapy prescribing and control in out-patient practice? Kardiologiia. 2015;55(6):34-9. (In Russ.).

8. Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Mar. CADTH Therapeutic Reviews. Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0060253/. Checked by Feb 10, 2017.

9. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of internal medicine. 2007;146(12):857-67.

10. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991;84(2):527-39.

11. Aguilar M., Hart R., Pearce L.A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;(3):CD006186.

12. Cameron C., Coyle D., Richter T., et al. Systematic review and networkmeta-analysis comparing antithrombotic agents for the prevention of stroke andmajor bleeding in patients with atrial fibrillation. BMJ Open. 2014;4(6):e004301.

13. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-78.

14. Olesen J.B., Lip G.Y., Lindhardsen J., et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thrombosis and Haemostasis. 2011;106(4):739-49.

15. Själander S., Själander A., Svensson P.J., Friberg L. Atrial fibrillation patients do not benefit from acetylsalicylic acid. Stroke. 2009;40:1410-6.

16. Sato H., Ishikawa K., Kitabatake A., et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2):447-51.

17. Segal J.B., McNamara R.L., Miller M.R., et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 2000;15:56-67.

18. Andersen L.V., Vestergaard P., Deichgraeber P., et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 2008; 94:1607-13.

19. Zhang J.T., Chen K.P., Zhang S. Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore). 2015;94(4):e409.

20. Vazquez F.J., Gonzalez J.P., LeGal G., et al. Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. Thromb Res. 2016;138: 1-6.

21. Warkentin A.E., Donadini M.P., Spencer F.A., et al. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis. J Thromb Haemost. 2012;10(4): 512-20.

22. Tawfik A., Bielecki J.M., Krahn M., et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol. 2016;8:93-107.

23. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med.2011;364(9):806-17.

24. Kirchhof P., Benussi S., Kotecha D., et al. Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.

25. Hobbs F.R., Taylor C.J., Jan Geersing G., et al. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J PrevCardiol. 2016;23(5):460-73.

26. Flaker G.C., Gruber M., Connolly S.J., et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152(5):967-73.

27. Dentali F., Riva N., Crowther M., et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20): 2381-91.

28. . Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633.

29. Manning W.J., Singer D.E., Lip G.Y.H. Atrial fibrillation: Anticoagulant therapy to prevent embolization. UpToDate. Available at: http://www.uptodate.com/contents/atrial-fibrillation-anticoagulanttherapy-to-prevent-embolization. Checked by Feb 10, 2017.

30. Kumar S., Danik S.B., Altman R.K., et al. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. Cardiol Rev. 2016;24(5):218-23.

31. Lane D.A., Raichand S., Moore D., et al. Combined anticoagulation and antiplatelet therapy for highrisk patients with atrial fibrillation: a systematic review. Health Technol Assess. 2013;17(30):1-188.

32. vanWalraven C., Hart R.G., Connolly S., et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410-6.

33. Rash A., Downes T., Portner R., et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation(WASPO). Age Ageing. 2007;36:151-6.

34. Vazquez F.J., Gonzalez J.P., Gándara E. Aspirin compared to low intensity anticoagulation in patients with non-valvularatrial fibrillation. A systematic review and meta-analysis. PLoS One. 2015 12;10(11):e0142222.

35. Eckman M.H., Lip G.Y., Wise R.E., et al. Using an atrial fibrillation decision support tool for thromboprophylaxis in atrial fibrillation: effect of sex and age. J Am Geriatr Soc. 2016;64(5):1054-60.

36. Sarafoff N., Byrne R. A., Sibbing D. Clinical use of clopidogrel. Current Pharmaceutical Design. 2012;18(33):5224-39.

37. Diagnostics and Treatment of Atrial Fibrillation. Russian Guidelines. Moscow: VNOAandACVS; 2012. (In Russ.) Диагностика и лечение фибрилляции предсердий. Национальные рекомендации. М.: ВНОАиАССХ; 2012.

38. Edholm K., Ragle N., Rondina M.T. Antithrombotic management of atrial fibrillation in the elderly. Med Clin North Am. 2015;99(2):417-30.

39. Fernández S.C., Formiga F., Camafort M. Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. BMC Cardiovascular Disorders 2015;15:143.

40. O'Mahony D., O'Sullivan D., Byrne S., et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(N2):213-8.

Документы

Информация

Автор

Е. А. Ушкалова Российский университет дружбы народов
С. К. Зырянов Российский университет дружбы народов
Е. В. Думченко Российский университет дружбы народов

Название журнала

Рациональная Фармакотерапия в Кардиологии

Ключевые слова

Статья